Medium-chain triglycerides improve cognition and metabolism in Alzheimer’s mice

Overview

Dietary supplementation with medium-chain triglycerides (MCT) enhances cognitive function and systemic metabolism in Alzheimer’s disease (AD) mouse models without increasing circulating ketone levels. Both MCT and ketogenic diets improved hippocampal-dependent memory and neuronal structure but exerted distinct metabolic effects.

Background

Alzheimer’s disease is characterized by progressive cognitive decline and brain changes including impaired glucose metabolism. Ketogenic diets, which elevate ketone bodies as alternative brain fuel, have shown promise in mitigating AD symptoms but can be difficult to implement. MCT supplementation offers a potential alternative by increasing medium-chain fatty acids and ketones without carbohydrate restriction. However, the mechanisms underlying MCT benefits and their relationship to ketone levels remain unclear, especially in the context of AD.

Data Highlights

Key Findings

• MCT supplementation and ketogenic diet both improved spatial learning and memory in AD mouse models.
• Both diets increased dendritic spine density and modulated hippocampal genes related to mitochondria, synapses, and insulin signaling.
• MCT did not raise circulating ketone levels, unlike the ketogenic diet, indicating different mechanisms of action.
• MCT enhanced peripheral insulin sensitivity, whereas the ketogenic diet exacerbated hyperglycaemia, weight gain, and adiposity.
• Both diets partially reversed AD-associated hepatic metabolic disturbances but via distinct pathways: MCT downregulated cholesterol-related genes; ketogenic diet induced lipid depletion and proinflammatory gene expression.

Clinical Implications

MCT supplementation may offer cognitive and metabolic benefits in AD without the challenges of inducing ketosis, making it a potentially more tolerable dietary intervention. Its ability to improve peripheral insulin response suggests a dual benefit addressing both brain and systemic metabolic dysfunction in AD. Clinicians should consider MCT as an alternative or adjunct to ketogenic diets in managing AD-related cognitive decline.

Conclusion

MCT supplementation improves cognition and systemic metabolism in Alzheimer’s disease models through mechanisms distinct from classical ketogenic diets, notably without elevating ketone levels. These findings support further exploration of MCT as a feasible dietary strategy for AD management.

References

1. Original Article 2024 -- Medium-chain triglycerides enhance cognitive function and metabolic processes in Alzheimer’s disease mouse models